PPBT
Purple Biotech Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$1.75
−11.62%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 4.3M | 3.7M | 7.6M | 17.0M | 16.3M |
| SG&A Expense | 3.3M | 3.0M | 2.9M | 4.8M | 6.0M |
| General & Admin Expense | — | 3.0M | 2.9M | 4.8M | 6.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 20.7M | 20.7M | 450.0K | 393.0K | 321.0K |
| Total Operating Expenses | 28.4M | 27.5M | 11.0M | 22.3M | 22.6M |
| Cost and Expenses | 28.4M | 27.5M | 11.0M | 22.3M | 22.6M |
| Operating Income (EBIT) | (28.4M) | (27.5M) | (11.0M) | (22.3M) | (22.6M) |
| Non-Operating | |||||
| Interest Income | 222.0K | 227.0K | 260.0K | 474.0K | 532.0K |
| Interest Expense | 68.0K | 39.0K | 41.0K | 56.0K | 67.0K |
| Net Interest Income | 154.0K | 188.0K | 219.0K | 418.0K | 465.0K |
| Other Non-Op Income/Expense | 3.8M | 966.0K | 3.7M | 2.3M | 843.0K |
| Non-Operating Income (excl Interest) | (3.8M) | (1.0M) | (3.8M) | (2.4M) | (910.0K) |
| EBT (Pre-Tax Income) | (24.6M) | (26.5M) | (7.3M) | (20.0M) | (21.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (24.5M) | (26.4M) | (7.2M) | (19.9M) | (21.7M) |
| Earnings from Cont. Ops | (24.6M) | (26.5M) | (7.3M) | (20.0M) | (21.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (24.5M) | (26.4M) | (7.2M) | (19.9M) | (21.7M) |
| Per Share | |||||
| Basic EPS | ($2.22) | ($5.50) | ($4.42) | ($17.96) | ($24.00) |
| Diluted EPS | ($2.22) | ($5.50) | ($4.42) | ($17.96) | ($24.00) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 10.9M | 4.8M | 1.6M | 1.1M | 902830 |
| Diluted Shares Outstanding | 10.9M | 4.8M | 1.6M | 1.1M | 904050 |
| Profitability Metrics | |||||
| EBITDA | (24.3M) | (26.3M) | (7.1M) | (19.7M) | (21.5M) |
| D&A | 246.0K | 203.0K | 186.0K | 197.0K | 201.0K |
| EBIT | (24.5M) | (26.5M) | (7.2M) | (19.9M) | (21.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026